Salud financiera de hoja de balance de China Shineway Pharmaceutical Group
Salud financiera controles de criterios 5/6
China Shineway Pharmaceutical Group tiene un patrimonio de accionistas total de CN¥7.3B y una deuda total de CN¥330.0M, lo que sitúa su ratio deuda-patrimonio en 4.5%. Sus activos y pasivos totales son CN¥9.9B y CN¥2.5B respectivamente. El BAIT de China Shineway Pharmaceutical Group es de CN¥944.7M, por lo que su ratio de cobertura de intereses es de -5.7. Tiene efectivo e inversiones a corto plazo que ascienden a CN¥6.2B.
Información clave
4.5%
Ratio deuda-patrimonio
CN¥330.00m
Deuda
| Ratio de cobertura de intereses | -5.7x |
| Efectivo | CN¥6.23b |
| Patrimonio | CN¥7.34b |
| Total pasivo | CN¥2.55b |
| Activos totales | CN¥9.88b |
Actualizaciones recientes sobre salud financiera
Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13
China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10
Recent updates
China Shineway Pharmaceutical Group Limited's (HKG:2877) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Oct 18If EPS Growth Is Important To You, China Shineway Pharmaceutical Group (HKG:2877) Presents An Opportunity
Jun 03Is China Shineway Pharmaceutical Group (HKG:2877) A Risky Investment?
May 13China Shineway Pharmaceutical Group (HKG:2877) Has Announced That It Will Be Increasing Its Dividend To CN¥0.461
Apr 26Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 41%?
Apr 17China Shineway Pharmaceutical Group (HKG:2877) Is Increasing Its Dividend To CN¥0.461
Mar 31China Shineway Pharmaceutical Group Limited's (HKG:2877) 26% Price Boost Is Out Of Tune With Earnings
Mar 14Does China Shineway Pharmaceutical Group (HKG:2877) Deserve A Spot On Your Watchlist?
Jan 29China Shineway Pharmaceutical Group (HKG:2877) Seems To Use Debt Rather Sparingly
Sep 28China Shineway Pharmaceutical Group (HKG:2877) Is Paying Out A Dividend Of CN¥0.118
Sep 01We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Aug 03Are Investors Undervaluing China Shineway Pharmaceutical Group Limited (HKG:2877) By 44%?
May 30We Ran A Stock Scan For Earnings Growth And China Shineway Pharmaceutical Group (HKG:2877) Passed With Ease
Mar 07China Shineway Pharmaceutical Group's (HKG:2877) Dividend Will Be Reduced To CN¥0.125
Sep 01China Shineway Pharmaceutical Group Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 31China Shineway Pharmaceutical Group (HKG:2877) Has A Rock Solid Balance Sheet
Apr 07China Shineway Pharmaceutical Group's(HKG:2877) Share Price Is Down 55% Over The Past Three Years.
Mar 11Should You Buy China Shineway Pharmaceutical Group Limited (HKG:2877) For Its Dividend?
Feb 18Should You Use China Shineway Pharmaceutical Group's (HKG:2877) Statutory Earnings To Analyse It?
Jan 31Is China Shineway Pharmaceutical Group Limited (HKG:2877) Trading At A 49% Discount?
Jan 13What Is The Ownership Structure Like For China Shineway Pharmaceutical Group Limited (HKG:2877)?
Dec 25We Think China Shineway Pharmaceutical Group (HKG:2877) Can Manage Its Debt With Ease
Dec 10Reflecting on China Shineway Pharmaceutical Group's (HKG:2877) Share Price Returns Over The Last Five Years
Nov 25Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (CN¥8.5B) de 2877 superan a sus pasivos a corto plazo (CN¥2.4B).
Pasivo a largo plazo: Los activos a corto plazo de 2877 (CN¥8.5B) superan a sus pasivos a largo plazo (CN¥113.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: 2877 tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de 2877 ha crecido de 0% a 4.5% en los últimos 5 años.
Cobertura de la deuda: La deuda de 2877 está bien cubierta por el flujo de caja operativo (356.2%).
Cobertura de intereses: 2877 gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.